Attached files
| file | filename |
|---|---|
| EX-3.5 - EXHIBIT 3.5 - OPIANT PHARMACEUTICALS, INC. | v453683_ex3-5.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2016
OPIANT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55330 | 46-4744124 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number |
(IRS Employer Identification No.) |
|
401 Wilshire Blvd., 12th Floor, Santa Monica, CA |
90401 | |
|
(Address of Principal Executive Offices) |
(Zip Cope) |
Registrant’s telephone number, including area code
| (424) 252-4756 |
| (Former name or former address if changed since last report,) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On November 16, 2016, the board of directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) voted to amend and restate the Company’s Bylaws (the “Amended and Restated Bylaws”) to, effective as of November 16, 2016, (i) reflect the Company’s current name and (ii) augment Section 3.14 of the Bylaws to allow for e-mail or other electronic transmission consenting to an action to be taken by a director to be deemed to be a written, signed and dated consent of such director for the purposes of such Section 3.14.
The foregoing summary of the Amended and Restated Bylaws is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, which is attached hereto as Exhibit 3.5 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit |
| 3.5 | Amended and Restated Bylaws of Opiant Pharmaceuticals, Inc. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Opiant Pharmaceuticals, Inc. | ||
| Date: November 22, 2016 | By: | /s/ Dr. Roger Crystal |
| Name: Dr. Roger Crystal | ||
| Title: President and Chief Executive Officer |